(IN BRIEF) The Conference Forum announced the launch of the 8th annual Patients as Partners® Europe meeting, scheduled for May…
(IN BRIEF) Boehringer Ingelheim and Sosei Group Corporation (Sosei Heptares) have unveiled a global collaboration and exclusive option-to-license agreement aimed…
(IN BRIEF) Boehringer Ingelheim has reported compelling results from its Phase II trial of Survodutide, a novel glucagon/GLP-1 receptor dual…
(IN BRIEF) Boehringer Ingelheim has been honored by the Top Employers Institute with a "Global Top Employer" certification for the…
(IN BRIEF) Boehringer Ingelheim and IBM have formed a partnership to expedite the discovery of novel candidate antibodies for therapeutic…
(IN BRIEF) Pharmaceutical company Boehringer Ingelheim has declared its intention to move forward with survodutide, a dual agonist targeting the…
(IN BRIEF) Boehringer Ingelheim has begun construction on a new Chemical Innovation Plant at its headquarters in Ingelheim, Germany. The…
(IN BRIEF) The Conference Forum has announced that the 7th annual European Patients as Partners® in Clinical Research conference will…
(PRESS RELEASE) INGELHEIM, 17-Jan-2023 — /EuropaWire/ — Boehringer Ingelheim, one of the world's leading research-driven pharmaceutical companies with 130 years of…
(COMUNICADO DE PRENSA) INGELHEIM, 17-Jan-2023 — /EuropaWire/ — Boehringer Ingelheim, una de las principales compañías farmacéuticas del mundo impulsadas por la…
Metacam® 0.5mg/ml Oral Suspension for Cats is now also approved in Europe for alleviation of mild to moderate post-operative pain associated…
The programme was set up by the International Society of Feline Medicine (ISFM), the veterinary division of the charity International…
61% of IPF patients are worried or extremely worried about experiencing an acute IPF exacerbation1 Survey underlines the importance of…
New start-up as platform for digital transformation in data science, agile software development and user experience design Improvement of human…
Both companies will become global leaders in two different sectors of the pharmaceutical market Paris (France) and Ingelheim (Germany), 03-Jan-2017…
360 million people worldwide suffer from disabling hearing loss with no effective treatment available New collaboration with China Southeast University…
After 12 weeks, approximately twice as many patients with moderate-to-severe Crohn’s disease, the majority of whom had previously failed treatment…
• Approval provides a new oral treatment option for patients with the second largest sub-type of non-small cell lung cancer…
• Results of global Phase IIb LUX-Lung 7 trial demonstrate afatinib superior in reducing the risk of lung cancer progression…
Ingelheim, 20-11-2015 — /EuropaWire/ — Boehringer Ingelheim has been named one of the most innovative companies worldwide in 2015. For the…
Your Time campaign calls for earlier action in COPD WHO expects COPD to be the third leading cause of death…
OTEMTO® 1&2 post-hoc analysis reinforces quality of life benefits provided by Spiolto® Respimat® right from the initial stage when patients…
Not for audiences in the US and Canada LONDON, 26-8-2015 — /EuropaWire/ — This week, epgonline.org, the website for healthcare…
Ingelheim, Germany and Indianapolis, US, 24-8-2015 — /EuropaWire/ — Boehringer Ingelheim and Eli Lilly and Company today announced positive top-line results…
Initial combinations of empagliflozin and metformin in patients with T2D led to significant reductions in blood glucose vs. empagliflozin or…
In patients with no prior maintenance treatment, tiotropium/olodaterol Respimat® more than doubled the improvement in lung function* compared to Spiriva®…
CAMBRIDGE, Massachusetts and INGELHEIM, Germany, 14-4-2015 — /EuropaWire/ — Hydra Biosciences, Inc., a leader in the field of transient receptor potential (TRP)…
For Non-US/Non-UK/Non-Canadian Media New analyses highlight undertreatment of high-risk AF patients1,2 First Phase II data demonstrating anticoagulant prescribing patterns in…
• HOTLINE: New results from RE-LY® compare the effect of warfarin and Pradaxa® on kidney function in patients requiring anticoagulation…
For media outside of the US, the UK & Canada only The efficacy and safety profile of Pradaxa® (dabigatran etexilate)…
Ground-breaking ceremony for leading veterinary manufacturing plant in Taizhou/China Investment of 58 million Euro 200 job opportunities expected Taizhou, Jiangsu,…
Over 950 patients have now been successfully enrolled in the pivotal Phase III HCVerso™1 and 2 trials The Phase III…
For media outside of the US, the UK & Canada only Ingelheim, Germany, 26-8-2013 — /EuropaWire/ — Boehringer Ingelheim today announced the…
2-7-2013 — /europawire.eu/ — New Phase III data presented at the American Diabetes Association 73rd Scientific Sessions® (ADA) showed linagliptin improved…
Ingelheim, Germany and Indianapolis, US, 1-7-2013 — /europawire.eu/ — Boehringer Ingelheim and Eli Lilly and Company today announced results from a…